Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Perfect. Well, thanks, everyone, for joining us on the second day of the 43rd Annual Goldman Sachs Healthcare Conference. We're super pleased to have the management team from Madrigal with us. Paul Friedman, CEO; Alex Howarth, CFO; and Remy, CMO, with a last minute addition.
With that, maybe Paul, I'll turn it over to you if you'd like to make some opening remarks.
Well, I'd like to say that we have some very interesting data to be presented at EASL next week, going to be very busy there with 4 oral presentations and 2 posters. I guess -- and we'd go over them as we move through the Q&A.
Our program is well along into Phase III with resmetirom in a very late stage of the serial biopsy study that's needed to be able to use the data for a Subpart H NDA submission. We've guided to the fourth quarter for giving top line data for that study. And we're hoping and trying to have it be early in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |